Neogen Corp.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US6404911066
USD
5.93
0.01 (0.17%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Neogen Corp. stock-summary
stock-summary
Neogen Corp.
Pharmaceuticals & Biotechnology
Neogen Corporation develops, manufactures and markets a range of products and services dedicated to food and animal safety. The Company operates through two segments: Food Safety and Animal Safety. The Food Safety segment produces and markets diagnostic test kits and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens and levels of general sanitation. The Animal Safety segment is primarily engaged in the production and marketing of products dedicated to animal health, including a range of consumable products marketed to veterinarians and animal health product distributors. The Animal Safety segment also provides genetic identification services. Additionally, the Animal Safety segment produces and markets rodenticides, disinfectants and insecticides to assist in the control of rodents and disease in and around agricultural, food production and other facilities.
Company Coordinates stock-summary
Company Details
620 Lesher Pl , LANSING MI : 48912-1509
stock-summary
Tel: 1 517 3729200
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 104 Schemes (54.32%)

Foreign Institutions

Held by 135 Foreign Institutions (28.62%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. James Borel
Lead Independent Chairman of the Board
Mr. John Adent
President, Chief Executive Officer, Director
Dr. William Boehm
Independent Director
Dr. Ronald Green
Independent Director
Mr. G. Bruce Papesh
Independent Director
Mr. James Tobin
Independent Director
Ms. Darci Vetter
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
225 Million
(Quarterly Results - May 2025)
Net Profit:
-612 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 1,229 Million (Small Cap)

stock-summary
P/E

281.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.37

stock-summary
Return on Equity

-0.16%

stock-summary
Price to Book

0.59